Aptar Pharma buys Pulmotree after two-year partnership, but can Kolibri unlock inhaled biologics?
Aptar Pharma acquires Pulmotree to advance Kolibri inhaler technology for complex medicines. Commercial success depends on validation and adoption.
Pharma & Biotech